Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > video from RDW this am
View:
Post by DJDawg on May 30, 2024 11:24am

video from RDW this am

https://stockhouse.com/news/press-releases/2024/05/30/theralase-r-release-s-1q2024-financial-statements
Comment by Alamir1111 on May 30, 2024 11:44am
Love it Boy you're asking tough question today
Comment by Alamir1111 on May 30, 2024 12:19pm
Looks like they are committed  to enroll 100 patients which probably cost some moneyl it's kind of positive
Comment by Tapps21 on May 30, 2024 12:56pm
Why didn't she ask the toughest question? "Roger, how does Theralase plan to fund the rest of the planned trial, new sites etc..."
Comment by Alamir1111 on May 30, 2024 12:58pm
Tlt is a paid subscriber  to sh.
Comment by Alamir1111 on May 30, 2024 1:03pm
Independent  journalism paid by the sponsor 
Comment by gebremeskel on May 30, 2024 1:56pm
Why not DIY? Theralase® will be hosting a conference call on Thursday June 6 th , 2024 at 11:00 am ET , which will include a presentation of the financial and operational results for the fiscal quarter ending March 31 st , 2024. Questions are welcome; to ensure we have time to review and answer them during the call, please send them in advance to ...more  
Comment by Alamir1111 on May 30, 2024 2:12pm
Gebremeskel   2024, the Company plans to secure funding through various equity and debt instruments to allow the Company the ability to become base shelf eligible. This will allow the Company sufficient funding to complete enrollment into Study II by year end, data lock in mid 2026 and position the Company for FDA and Health Canada approval by the end of 2026, subject to achieving FDA ...more  
Comment by Alamir1111 on May 30, 2024 2:37pm
As a Fast Track designee, Theralase® will have access to early and frequent communications with the FDA to discuss Theralase's development plans and ensure timely collection of the appropriate clinical data to support the approval process. The accelerated communication with the FDA potentially allows, TLD-1433, in combination with the TLC-3200 medical laser system ("TLC-3200" ...more  
Comment by riverrrow on May 31, 2024 9:07am
I only watched the first few seconds.   Roger looked rarther glum.  He either has reason to be or he's a very good poker player.
Comment by plantrader on May 31, 2024 9:22am
If BTD is the key to the kingdom in the near-term, then why wouldn't this interview at least have included that milestone that is nearly a given according to the impressive clinical data? Instead they talk about 2 years from now? How about, we believe we're about to receive BTD approval from the FDA in the next few months along with completing enrollment of 100 patients, then ultimately ...more  
Comment by riverrrow on May 31, 2024 9:38am
I"m guessing Roger is afraid of saying something too optimistic that might cause him to be censured by the securities people, again.  TLT needs a new promoter who isn't carrying any baggage and who isn't afraid to sing the praises of Ruvidar. 
Comment by plantrader on May 31, 2024 9:41am
@river, Good point. That seems like a legit angle on it, and more positive than some other theories folks could come up with after such an obvious omission. Fine, as long as he didn't fail to mention it due to having lost confidence in receiving BTD for reasons we're unaware of.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250